Akèy › Kansè Poumon ki pa ti selil › Colorado › Denver
Etid klinik pou Kansè Poumon ki pa ti selil nan Denver, CO
27 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Denver (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Kaiser Permanente-Franklin, Denver
- National Jewish Health-Main Campus, Denver
- Rocky Mountain Cancer Centers - Swedish, Englewood · 6 mi lwen
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthOne, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Rocky Mountain Cancer Center, Denver
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Kaiser Permanente-Franklin, Denver
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers,LLP, Denver
- Rocky Mountain Cancer Centers LLP, Denver
- Rocky Mountain Cancer Centers LLP, Englewood · 6 mi lwen
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- Rocky Mountain Cancer Centers,LLP, Denver
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- The Melanoma and Skin Cancer Institute, Englewood · 6 mi lwen
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- National Jewish Health Medical Center, Denver
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- SCRI at HCA HealthONE, Denver
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Denver
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-872-E, Denver
- Local Institution - 007-872-I, Denver
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's, Denver
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthOne, Denver
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at HealthOne, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthONE, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute at HealthONE, Denver
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Denver
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI) at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- ak 1 plis
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Ap rekriteFaz 1
- Dren Investigational Site, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Denver
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Denver
- Kansè Metastatik29 etid
- Kansè nan tete29 etid
- Myelom Miltip27 etid
- Kansè kolorektal23 etid
- Melanom19 etid
- Kansè pwostat19 etid
- Kansè (tout kalite)18 etid
- Kansè ovè16 etid
- Kansè poumon16 etid
- Kansè Endomèt15 etid
- Limfòm Non-Hodgkin14 etid
- Kansè pankreyas13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.